Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab for Pyoderma Gangrenosum
NCT04274166Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- May 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of secukinumab in pyoderma gangrenosum (PG), sponsored by Wake Forest University Health Sciences. Planned start May 2021; status: withdrawn.
02
Drugs
secukinumab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT04274166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274166.